Dianthus Therapeutics Q2 net loss rises to $50.2 million from $31.6 million
Dianthus Therapeutics reported second-quarter 2026 results on August 4, 2026, with a net loss of $50.2 million, or $0.90 per share, compared with $31.6 million, or $0.88 per share, a year earlier. Research and development and general and administrative expenses both rose, which the company attributed to clinical costs and higher headcount for its claseprubart programs. The company said its roughly $1.2 billion in cash, cash equivalents and investments is projected to fund operations into 2030.
Key points
- Net loss of $50.2 million, or $0.90 per share, for the quarter ended June 30, 2026, versus $31.6 million, or $0.88 per share, a year earlier
- R&D expenses were $48.7 million, up from $26.3 million, mainly due to higher clinical costs and headcount
- G&A expenses were $13.6 million, up from $8.9 million, mainly due to increased headcount
- Cash, cash equivalents and investments were about $1.2 billion as of June 30, 2026, projected to provide runway into 2030
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.